Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1646 1674
This examiner grants 72% of resolved cases
Prema Maria Mertz, in Tech Center 1600 and Art Unit 1643, has 769 resolved cases. The allowance rate is 71.7 percent, and the interview lift is 35.4 percent. This 35.4 percent lift is very high compared to the 71.7 percent baseline. The 71.7 percent allowance rate is a strong baseline, which is significantly improved by the 35.4 percent lift, making interviews a highly recommended strategy.
The median time to allowance is 1013 days. Applicants have a 71.7 percent chance of success, which is greatly enhanced by the 35.4 percent interview lift. The 1013 day timeline is a standard expectation. With 769 resolved cases, the examiner's data is very consistent and highlights the importance of interviews. The 1013 day pendency and 35.4 percent lift are the key metrics for counsel to consider in Art Unit 1643. Utilizing the 35.4 percent lift is essential for success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17241935 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17786206 | Adalimumab Variants with Reduced Immunogenic Potential | Non-Final OA | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES |
| 18033464 | ANTIBODIES FOR USE IN THE DETECTION AND TREATMENT OF HEART DISEASE | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18252542 | METHODS OF TREATING AXL-EXPRESSING CANCERS WITH ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES | Non-Final OA | BIOATLA, INC. |
| 18518192 | VISTA ANTIGEN-BINDING MOLECULES | Non-Final OA | Hummingbird Bioscience Pte. Ltd. |
| 18604963 | IL-2 MUTEINS AND USES THEREOF | Non-Final OA | Pandion Operations, Inc. |
| 18585285 | IL-2 MUTEINS AND USES THEREOF | Non-Final OA | Pandion Operations, Inc. |
| 18597286 | METHODS OF TREATING ATOPIC DERMATITIS | Non-Final OA | Receptos LLC |
| 18277996 | MULTI-DOMAIN FUSION PROTEIN AND USE THEREOF | Non-Final OA | ZHEJIANG DOER BIOLOGICS CO., LTD. |
| 18265781 | BISPECIFIC ANTIBODIES BINDING TO CD7 AND CD33 | Non-Final OA | BIVICTRIX LIMITED |
| 18253197 | HEAVY CHAIN ANTIBODIES BINDING TO FOLATE RECEPTOR ALPHA | Non-Final OA | TENEOSEVEN, INC. |
| 17758279 | IMMUNOGENIC CONJUGATE INTENDED TO INDUCE AN IMMUNE RESPONSE DIRECTED AGAINST INTERLEUKIN-6 | Non-Final OA | PEPTINOV |
| 17758281 | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF POST-SURGICAL PAIN | Non-Final OA | PEPTINOV |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy